Long-Term Prognosis of Patients with Heart Failure: Follow-Up Results of Journey HF-TR Study Population

Anatol J Cardiol. 2023 Jan;27(1):26-33. doi: 10.14744/AnatolJCardiol.2022.2171.

Abstract

Background: Despite advances in therapeutic management of patients with heart failure, there is still an increasing morbidity and mortality all over the world. In this study, we aimed to present the 3-year follow-up outcomes of patients included in the Journey HF-TR study in 2016 that has evaluated the clinical characteristics and management of patients with acute heart failure admitted to the hospital and present a national registry data.

Methods: The study was designed retrospectively between November 2016 and December 2019. Patient data included in the previously published Journey HF-TR study were used. Among 1606 patients, 1484 patients were included due to dropout of 122 patients due to inhospital death and due to exclusion of 173 due to incomplete data. The study included 1311 patients. Age, gender, concomitant chronic conditions, precipitating factors, New York Heart Association, and left ventricular ejection fraction factors were adjusted in the Cox regression analysis.

Results: During the 3-year follow-up period, the ratio of hospitalization and mortality was 70.5% and 52.1%, respectively. Common causes of mortality were acute decompensation of heart failure and acute coronary syndrome. Angiotensin receptor blockers, betablockers, statin, and sacubitril/valsartan were found to reduce mortality. Hospitalization due to acute decompensated heart failure, acute coronary syndrome, lung diseases, oncological diseases, and cerebrovascular diseases was associated with the increased risk of mortality. Implantation of cardiac devices also reduced the mortality.

Conclusions: Despite advances in therapeutic management of patients with heart failure, our study demonstrated that the long-term mortality still is high. Much more efforts are needed to improve the inhospital and long-term survival of patients with chronic heart failure.

MeSH terms

  • Acute Coronary Syndrome* / drug therapy
  • Angiotensin Receptor Antagonists / therapeutic use
  • Follow-Up Studies
  • Heart Failure*
  • Humans
  • Prognosis
  • Retrospective Studies
  • Stroke Volume
  • Tetrazoles / adverse effects
  • Treatment Outcome
  • Ventricular Function, Left

Substances

  • Tetrazoles
  • Angiotensin Receptor Antagonists